Navigation Links
SynCo Bio Partners Signs New Manufacturing Agreements to Supply the US Market; Securing its Position as a Market Leader in Microbial Biopharmaceutical Contract Production
Date:2/2/2010

AMSTERDAM, February 2 /PRNewswire/ -- SynCo Bio Partners B.V. today announced that it has signed two commercial manufacturing agreements with an undisclosed US biopharmaceutical company. Under the contract, SynCo will provide both process validation and GMP commercial manufacturing services to support the commercial launch of two separate biopharmaceutical products onto the US market.

SynCo has commenced with preparations for the manufacture of conformance lots in advance of its client's BLA filings, expected in late 2010, in anticipation of commercial manufacturing commencing in 2011.

The products are both recombinant proteins, to be produced in E. coli. These products will be manufactured in SynCo's large-scale GMP facility and take the tally of marketed products manufactured at its Amsterdam facilities to six, since SynCo's inception in 2000. SynCo has previously supported process development efforts for both products; an excellent example of how SynCo supports its clients' biopharmaceutical development programs from early stage to commercial supply.

Pierre Warffemius, CEO of SynCo Bio Partners said, "This news is a further example of how SynCo can offer a viable long-term manufacturing choice to its clients. SynCo has grown steadily over the last ten years in a very competitive market. The foundation of this growth has been our ability to form strong and mutually beneficial relationships with our clients. As a consequence, SynCo is one of few biopharmaceutical CMOs in the world with a recognized track record in both clinical and commercial manufacturing, providing financial stability that allows us to continuously invest in our facilities."

About SynCo Bio Partners B.V.

SynCo Bio Partners is a GMP-licensed bulk drug substance and final product CMO with clinical and commercial production experience in mammalian and microbial systems. This experience has been acquired by developing new production processes for a number of international clients and producing a wide variety of vaccines, recombinant proteins and live bacterial products in our state-of-the-art, GMP-licensed facilities since inception in 2000.

Focused solely on biopharmaceuticals, SynCo acts as a strategic, long-term partner delivering product on time to the highest quality standards. SynCo's team is committed to exceeding customer expectations, taking a truly collaborative approach to contract manufacturing.

For more information, please visit http://www.syncobiopartners.com

SOURCE SynCo Bio Partners B.V.


'/>"/>
SOURCE SynCo Bio Partners B.V.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SynCo Bio Partners Completes Manufacture and Release of ActoGeniX Lead Product for Phase II Clinical Trials
2. SynCo Bio Partners Wins Best Contract Manufacturing Organization 2009 ViE Award
3. SynCo Bio Partners Increases its Capacities by Expanding its Quality Team
4. SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes
5. SynCo Bio Partners Enters the Japanese Market as it Signs its First Agreement With a Japanese Pharmaceutical Company
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
9. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
10. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
11. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 08, 2016 , ... From wearable devices that can improve ... On Thursday, December 15th a panel of entrepreneurs, innovators and a Philadelphia Eagles ... a Smart Talk session. Smart Talk will run from 8:30 – 10:30 a.m. ...
(Date:12/8/2016)... 2016 Eurofins announces the appointment of Sean Murray ... Scientific Inc. (ESI). Mr. Murray will bring valuable ... entrepreneurial experience in leading international business teams. As the National Division ... to uphold Eurofins, status as the global leader in bio-analytical testing ... , , ...
(Date:12/8/2016)... Oxford Gene Technology (OGT), ... panel range with the launch of the SureSeq myPanel™ NGS ... variants in familial hypercholesterolemia (FH). The panel delivers single nucleotide ... single small panel and allows customisation by ,mix and match, ... for LDLR , P C SK9 ...
(Date:12/8/2016)... ... December 08, 2016 , ... Microbial genomics leader, uBiome, ... is one of just six company finalists in the Health & Medicine category. ... companies nominated as finalists in this year’s awards include Google, SpaceX, Oculus, and ...
Breaking Biology Technology:
(Date:12/2/2016)... India , December 1, 2016 ... Authentication type (Fingerprint, Voice), Future Technology (Iris Recognition ... and Region - Global Forecast to 2021", published ... USD 442.7 Million in 2016, and is projected ... at a CAGR of 14.06%.      ...
(Date:11/29/2016)... 2016 BioDirection, a privately held medical device ... objective detection of concussion and other traumatic brain injury ... a meeting with the U.S. Food and Drug Administration ... Package. During the meeting company representatives reviewed plans for ... to commencement of a planned pilot trial. ...
(Date:11/24/2016)... , Nov. 23, 2016 Cercacor today introduced ... and their trainers non-invasively measure hemoglobin, Oxygen ... Rate, and Respiration Rate in approximately 30 seconds. Smaller ... easy and immediate access to key data about their ... a training regimen. Hemoglobin carries oxygen ...
Breaking Biology News(10 mins):